Healthcare Realty Trust stock
HRNYSEHealthcare Realty Trust Incorporated, Real EstateISIN US42226K1051
46Score 46 out of 100, Weak
Price and trend
63 / 100
Price history
+5.1% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.2% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 12% below its 52-week high. Largest decline in 20 years: 71% (February 2007 to March 2009).
Chart figures for advanced users
- SMA 50$18.17
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$18.94
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.34
- The lowest closing price of the last twelve months.
- Resistance$21.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Healthcare Realty Trust Incorporated belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $6.65B, is number 7 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.18B (down 6.9% year on year) and a loss of $246.07M.
- For fiscal 2026, analysts expect on average revenue of $1.1B (down 6.8%) and adjusted earnings per share of −$0.11.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 248 of 327 in Real Estate, median 55.
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $25.52, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 18.8% a year since 2020, REIT (Healthcare Facilities) median 10.2%.
Weaknesses
- DilutionShare count up 60% since 2020.Capital allocation 20
- Loss-makingLoss of $44.93M over the last 12 months.Fundamentals 55
- Turned to a lossEarnings per share from $0.24 in 2020 to −$0.71.Growth 39
Its standout strength is valuation, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $21.27 and expensive above $31.90 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $27.38 (cash-flow model) and $23.66 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $23.26, at 7.8% it would be $28.90.
Possible value trap: looks cheap, but score below 50.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.9). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 5.8% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 18.8% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −34%, operating 8%, net −21%. Last 12 months: net −4%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 29 Oct 2026EPS reported −$0.05 (expected $0.01)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 14.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.11−14.1%
- Revenue
- $1.1B0.0%
- Earnings per share
- $0.08−2.9%
- Revenue
- $1.14B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −4.6%2026 normalized FFO per share guidance raised by $0.02 to $1.64 at the midpoint, same-store cash NOI growth outlook raised to 4.25% to 5%.
“Turning to guidance, which you can find on page 11 of our supplemental report, we increased full year normalized FFO per share guidance by $0.02 to $1.64 at the midpoint, and we increased the upper end of the range to $1.66 per share.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $926,184 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Healthcare Realty Trust
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
327 rated companies in Real Estate
- This company
- 46
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- Omega Healthcare InvestorsOHI $14.64B67
- Healthpeak PropertiesDOC $14.05B53
- American Healthcare REITAHR $13B56
- CareTrust REITCTRE $9.95B67
- AedificaAED.BR $6.09B62
- Sabra Health Care REITSBRA $5.49B50
- National Health InvestorsNHI $3.24B61
- LTC PropertiesLTC $2.47B71
ETFs that hold Healthcare Realty Trust
Held by 18 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares US Property Yield UCITS ETFIQQ7 | 0.55% | 0.40% | €554.91M |
| VanEck Global Real Estate UCITS ETFTRET | 0.46% | 0.25% | €475.2M |
| State Street SPDR Dow Jones Global Real Estate UCITS ETF (Acc)SPY2 | 0.39% | 0.40% | €52.83M |
Show 5 more
| iShares Developed Markets Property Yield UCITS ETFIQQ6 | 0.36% | 0.59% | €812.71M |
| HSBC FTSE EPRA NAREIT Developed UCITS ETFH4ZL | 0.32% | 0.24% | €3.36B |
| Amundi FTSE EPRA NAREIT Global UCITS ETF Dist10AJ | 0.32% | 0.24% | €603.52M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.19% | 0.30% | €5.27B |
| UBS FTSE EPRA Nareit Developed Green UCITS ETF USD disCSYZ | 0.09% | 0.25% | €207.23M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.